Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GSK1265744 Na Salt Tablets
GSK1265744 Na Salt · 1 trial · 1 indication
Plasma GSK1265744 PK parameters: area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time AUC(0-infinity); AUC from time zero to time t, AUC(0-t), and maximum observed concentration, Cmax.
| Arm | Type | Description |
|---|---|---|
| GSK1265744 Na Salt Tablets | EXPERIMENTAL | Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water. |
| GSK1265744 Free Acid Nanomilled Capsules | EXPERIMENTAL | Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water. |
| GSK1265744 Free Acid Micronized Capsules | EXPERIMENTAL | Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water. |
| Name | Type | Description |
|---|---|---|
| GSK1265744 Na Salt Tablets | DRUG | Each tablet contains 30 mg of GSK1265744 sodium salt and excipients. |
| GSK1265744 Free Acid Nanomilled Capsules | DRUG | Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients. |
| GSK1265744 Free Acid Micronized Capsules | DRUG | Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients. |
Inclusion Criteria: * Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin =\< 1.5x upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * Healthy as determined by a responsible and experienced physician, bas...
GSK1265744 Na Salt is an investigational small molecule developed by GSK plc for infections, human immunodeficiency virus (HIV) and hepatitis. It is in Phase 1 clinical development and has been studied in a relative bioavailability trial of its tablet formulations. It is also known as GSK1265744 Na Salt Tablets.
GSK1265744 Na Salt is being developed for infections, human immunodeficiency virus (HIV) and hepatitis. Its only recorded clinical study enrolled healthy adult volunteers rather than patients, and it was designed to compare the relative bioavailability of different formulations of the drug.
GSK1265744 Na Salt is developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 1 relative bioavailability study of the drug's formulations, which was conducted in the United States.
GSK1265744 Na Salt is in Phase 1 clinical development. It is investigational and has not been approved for any indication. One Phase 1 trial has been completed, and no active trials are currently recorded for this asset.
GSK1265744 Na Salt has been studied in one completed Phase 1 trial, NCT01648257, titled Relative Bioavailability Study of GSK1265744 Formulations. The trial enrolled 18 healthy adult volunteers of all sexes in the United States and used a controlled, randomized design without double blinding.
Yes, GSK1265744 Na Salt Tablets is another name for GSK1265744 Na Salt. The tablet form was the formulation evaluated in the completed Phase 1 relative bioavailability study NCT01648257, which compared formulations of the drug in 18 healthy volunteers.